EGFR and lung carcinoma: For instance, the identification of epidermal growth factor receptor (EGFR) kinase domain activating mutations, conferring sensitivity to EGFR tyrosine kinases inhibitors, changed the lung cancer treatment paradigm and contributed to increased progression-free survival (PFS) and quality of life in this subgroup of patients [4].